Monitoring of liver metabolic function during interferon-alpha therapy and its relationship to treatment outcome in chronic hepatitis C patients

Hepato-Gastroenterology

Volumn 49, Issue 45, 2002, Pages 778-782

  Giannini, Edoardo ^a   Fasoli, Alberto ^a   Romagnoli, Paola ^a   Botta, Federica ^a   Fumagalli, Alessandra ^a   Polegato, Simone ^a   Sola, Simona ^a   Ceppa, Paola ^a   Testa, Roberto ^a  

^a Gastroenterology Unit   (Italy)

Author keywords

Chronic Hepatitis C; Cytochrome P 450; Interferon; Liver; MEGX

Indexed keywords

ALPHA INTERFERON; DEETHYLLIDOCAINE; ANTIVIRUS AGENT; DIAGNOSTIC AGENT; DRUG DERIVATIVE; LIDOCAINE;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; FEMALE; HEPATITIS C; HUMAN; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER METABOLISM; MALE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; METABOLISM; MIDDLE AGED;

ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMAN; INTERFERON-ALPHA; LIDOCAINE; LIVER FUNCTION TESTS; MALE; MIDDLE AGE; TREATMENT OUTCOME; HUMANS; MIDDLE AGED;

EID: 0036016772     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Biological basis for the clinical use of interferons
2. The science, economics, and effectiveness of combination therapy for hepatitis C
3. Interferon-α-2a. A review of its pharmacological properties and therapeutic use in the management of viral hepatitis
4. Inhibition of antipyrine metabolism by interferon
5. Inhibition of theophylline metabolism by interferon
6. Effects of alpha interferon on theophylline pharmacokinetics and metabolism
7. Interferon suppresses erythromycin metabolism in rats and human subjects
8. Effects of interferon-α on cytochrome P-450 isoforms 1A2 and 3A activities in patients with chronic hepatitis C
9. Depression of drug metabolizing activity in the human liver by interferon-α
10. Depression of Drug-metabolizing activity in the human liver by interferon-β
11. Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans
12. Use of hepatic lidocaine metabolism to monitor patients with chronic liver disease
13. Histological determinants of monoethylglycinexylidide formation in patients with chronic hepatitis C
14. Predictors of one-year pretransplant survival in patients with cirrhosis
15. Measuring lidocaine metabolite monoethylglycinexylidide as a quantitative index of hepatic function in adults with chronic hepatitis and cirrhosis
16. Formation kinetics of the lidocaine metabolite (MEGX) in patients with chronic active hepatitis and cirrhosis
17. Hepatic lidocaine metabolism and liver histology in patients with chronic hepatitis and cirrhosis
18. Monoethylglycinexylidide test: A prognostic indicator of survival in cirrhosis
19. Monoethylglycinexylidide formation measurement as a hepatic function test to assess severity of chronic liver disease
20. A proposed system for the nomenclature of hepatitis C virus genotypes
21. Can the MEGX test and serum bile acids improve the prognostic ability of Chid-Pugh's score in liver cirrhosis?
22. Histological grading and staging of chronic hepatitis
23. Effect of interferon alfa-2b therapy for hepatitis C on histology and lidocaine metabolism
24. Chronic liver disease related to hepatitis C virus age of patients seems to be the main determinant of severity independently of viral genotype
25. Antipyrine clearance and response to interferon treatment in patients with chronic active hepatitis C
26. Influence of gender on the monoetylglycinexylodide test in normal subjects and liver donors
27. Relationship between the antiviral effects of interferons and their abilities to depress cytochrome P-450